Circ‐ERBB2 knockdown sensitized colorectal cancer cells to 5‐FU via miR‐181a‐5p/PTEN/Akt pathway

Abstract

Colorectal cancer (CRC) is the fourth most deadly cancer worldwide, drug resistance impedes treatment of CRC. It is still urgent to find new molecular targets to improve the sensitivity of chemotherapeutic drugs. In this study, circ‐ERBB2 was upregulated in CRC cells. Upregulation of circ‐ERBB2 promoted CRC cells proliferation and clone formation, but inhibited apoptosis. We identified miR‐181a‐5p as circ‐ERBB2's target. The effect of miR‐181a‐5p on CRC cells was contrary to circ‐ERBB2, miR‐181a‐5p downregulation abolished the function of circ‐ERBB2 silencing in CRC cells. In addition, phosphatase and tensin homolog (PTEN) was verified as miR‐181a‐5p's downstream target, circ‐ERBB2 activates the Akt pathway and inhibits cell apoptosis through modulating miR‐181a‐5p/PTEN. Circ‐ERBB2 silencing significantly reduced CRC cell resistance to 5‐FU. miR‐181a‐5p downregulation abolished the role of circ‐ERBB2 knockdown in CRC cell resistance to 5‐FU. In conclusion, upregulation of circ‐ERBB2 promoted the malignancy of CRC and reduced CRC cell resistance to 5‐FU. Besides, additional mechanism study provided a novel regulatory pathways that circ‐ERBB2 knockdown promoted CRC cell sensitivity to 5‐FU by regulating miR‐181a‐5p/PTEN/Akt pathway. This research indicated that circ‐ERBB2 may be a valuable biomarker for the diagnosis and treatment of CRC.